Hemostemix Stock Performance
| HEM Stock | CAD 0.07 0.01 11.76% |
On a scale of 0 to 100, Hemostemix holds a performance score of 4. The company retains a Market Volatility (i.e., Beta) of -0.81, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Hemostemix are expected to decrease at a much lower rate. During the bear market, Hemostemix is likely to outperform the market. Please check Hemostemix's sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Hemostemix's current trending patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Hemostemix are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Hemostemix showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Dividend Date 2020-12-30 | Last Split Date 2020-12-30 |
1 | Hemostemix Trading Down 5.6 percent - Defense World | 09/19/2024 |
2 | Hemostemix Secures 1.8M in Private Placement - TipRanks | 11/05/2024 |
| Begin Period Cash Flow | 135.7 K |
Hemostemix |
Hemostemix Relative Risk vs. Return Landscape
If you would invest 7.00 in Hemostemix on September 1, 2024 and sell it today you would earn a total of 0.50 from holding Hemostemix or generate 7.14% return on investment over 90 days. Hemostemix is currently producing 0.6833% returns and takes up 10.8688% volatility of returns over 90 trading days. Put another way, 96% of traded stocks are less volatile than Hemostemix, and 87% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Hemostemix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hemostemix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Hemostemix, and traders can use it to determine the average amount a Hemostemix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0629
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HEM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.87 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.68 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Hemostemix is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hemostemix by adding it to a well-diversified portfolio.
Hemostemix Fundamentals Growth
Hemostemix Stock prices reflect investors' perceptions of the future prospects and financial health of Hemostemix, and Hemostemix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hemostemix Stock performance.
| Return On Asset | -3.49 | ||||
| Current Valuation | 15.05 M | ||||
| Shares Outstanding | 123.98 M | ||||
| Price To Earning | (1.70) X | ||||
| Price To Book | 27.76 X | ||||
| EBITDA | (2.16 M) | ||||
| Net Income | (2.5 M) | ||||
| Cash And Equivalents | 49.36 K | ||||
| Total Debt | 4.32 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (1.5 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Market Capitalization | 9.3 M | ||||
| Total Asset | 313.76 K | ||||
| Retained Earnings | (63.27 M) | ||||
| Working Capital | (2.56 M) | ||||
About Hemostemix Performance
Evaluating Hemostemix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Hemostemix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hemostemix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (130.65) | (137.19) | |
| Return On Tangible Assets | (7.97) | (8.37) | |
| Return On Capital Employed | 0.91 | 0.96 | |
| Return On Assets | (7.97) | (8.37) | |
| Return On Equity | 0.34 | 0.36 |
Things to note about Hemostemix performance evaluation
Checking the ongoing alerts about Hemostemix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hemostemix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hemostemix is way too risky over 90 days horizon | |
| Hemostemix has some characteristics of a very speculative penny stock | |
| Hemostemix appears to be risky and price may revert if volatility continues | |
| Hemostemix has high likelihood to experience some financial distress in the next 2 years | |
| Hemostemix has accumulated 4.32 M in total debt. Hemostemix has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Hemostemix until it has trouble settling it off, either with new capital or with free cash flow. So, Hemostemix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hemostemix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hemostemix to invest in growth at high rates of return. When we think about Hemostemix's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hemostemix has accumulated about 49.36 K in cash with (1.5 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: Hemostemix Secures 1.8M in Private Placement - TipRanks |
- Analyzing Hemostemix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hemostemix's stock is overvalued or undervalued compared to its peers.
- Examining Hemostemix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hemostemix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hemostemix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hemostemix's stock. These opinions can provide insight into Hemostemix's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.